MedTrace Logo

Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry

NCT00297219 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 457

Last updated 2009-08-04

No results posted yet for this study

Summary

The high rate of cardiovascular complications in the dialysis population cannot be explained by traditional cardiovascular risk factors. One of such factors proposed to contribute to the cardiovascular mortality in dialysis patient population is vascular calcification possibly resulting from disturbances of calcium-phosphate metabolism.

The aim of this study is to assess the effects of treatment with dialysate containing 1.75 or 1.5 mmol/L to 1.25 mmol/L calcium regarding coronary artery calcification and bone histomorphometry in hemodialysis patients.

Conditions

  • End-Stage Renal Disease
  • Hemodialysis

Interventions

DRUG

Low dialysate calcium

1.25 mmol/L dialysate calcium

DRUG

high dialysate calcium

1.75 mmol/L dialysate calcium

Sponsors & Collaborators

  • University of Kentucky

    collaborator OTHER

  • Fresenius Medical Care North America

    collaborator INDUSTRY

  • Ege University

    lead OTHER

Principal Investigators

  • Ercan Ok, MD · Ege University School of Medicine Nephrology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297219 on ClinicalTrials.gov